Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival Sep 07, 2023
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL Study suggests "watch and wait" should remain standard of care Jun 28, 2023
Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivors A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
Blinatumomab Plus Chemo Effective in Aggressive Infant ALL Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
Year in Review: Acute Lymphoblastic Leukemia New ways to use CAR T-cell therapy and treatment de-intensification strategies Dec 05, 2022
New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
Two More Patients With HIV Surviving Without Antiretrovirals Functional cures now seen in 5 patients Jul 29, 2022
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kids Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
